Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tezepelumab for bronchiolitis obliterans syndrome after allogeneic stem cell transplantation
2024-516796-33-00Phase 2Authorised
- Sponsor
- Hôpital Foch
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tezepelumab in Bronchiolitis Obliterans Syndrome (BOS), sponsored by Hôpital Foch. Primary endpoint: Within-patient change in annualized number of bronchial exacerbations. Planned start May 2026; status: authorised.
02
Drugs
03
Conditions
Bronchiolitis Obliterans Syndrome (BOS)
Beyond the preview
Go deeper on 2024-516796-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516796-33-00.